Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

AZD-8055

AZD8055 has been used in trials studying the treatment of Cancer, Lymphomas, Solid Tumors, MALIGNANT GLIOMA, and brainstem glioma, among others.

AZD8055 has been used in trials studying the treatment of Cancer, Lymphomas, Solid Tumors, MALIGNANT GLIOMA, and brainstem glioma, among others.

No indication information available.

No associated conditions information available.

Title	Posted	Study ID	Phase	Status	Sponsor
AZD8055 for Adults With Recurrent Gliomas	2011/03/16	NCT01316809	Phase 1	Completed	National Cancer Institute (NCI)
Preliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced Tumours	2010/09/02	NCT01194193	Phase 1	Withdrawn	AstraZeneca
Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer Patients	2009/10/22	NCT00999882	Phase 1	Completed	AstraZeneca
Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055	2009/09/09	NCT00973076	Phase 1	Completed	AstraZeneca
A Study of Tor Kinase Inhibitor in Advanced Tumors	2008/08/08	NCT00731263	Phase 1	Completed	AstraZeneca

Product Name	Manufacturer	Route	Strength	Approved	NDC Code

No FDA products found for this drug

Medicine Name	EMA Number	Auth. Holder	Country	Drug Type	Status	Issued	Opinion	Revision

No EMA products found for this drug

Product Name	Manufacturer	Dosage Form	Strength	Approved	Approval No.	Online

No Singapore products found for this drug

No news found

Stay informed with timely notifications on clinical trials and research advancements.